Share this article

Data intelligence platform TrialHub has partnered with EmVenio Research to bolster subject participation and expedite site selection for clinical trials.

Under the partnership, TrialHub will offer insights of patients on real-time basis and will aid EmVenio in carrying out an extensive range of trials of novel life-saving therapies. 

TrialHub Operations head Ralitsa Vaskova said: “We are delighted to welcome EmVenio on board and help their dedicated team of experts expand clinical trial access to underrepresented and underserved patient communities.”

Leveraging the data intelligence gathering platform of TrialHub, EmVenio can seamlessly locate the suitable markets to recruit trial subjects required to satisfy the participation targets of clinical research organisations and pharmaceutical sponsors.

Benchmarking and statistics from TrialHub will offer a comprehensive feasibility outline of the clinical research setting. 

This approach aids EmVenio in efficiently choosing trial sites as per incidence of the disease, rates of enrolment and accessibility to healthcare providers and facilities that are readily available.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

EmVenio Research president Thad Wolfram said: “With TrialHub’s uniquely curated data, EmVenio can connect CROs and sponsors to the appropriate population of potential trial participants for a range of studies across a wide array of therapeutic areas. 

“Faster and more intelligent access to data allows us to quickly identify and recommend the best communities in which to conduct a trial and activate it in a more efficient manner, saving our clients time and money and providing them the results they need sooner than later.”